Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of nivolumab added to neoadjuvant chemoradiotherapy and mFOLFOX in locally advanced rectal cancer
MOH_2019-02-07_005941Phase 2Recruiting
- Sponsor
- פרופ' ברוך ברנר
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in rectal adenocarcinoma, sponsored by פרופ' ברוך ברנר. Started Sep 2018; status: recruiting.
02
Drugs
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on MOH_2019-02-07_005941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-07_005941.